Axis-Shield on course for 9% revenue growth
Scotland-based in vitro diagnostics firm Axis-Shield has released a financial update for the year ending December 31, 2007, ahead of its preliminary results announcement, expected on March 10, 2008. The firm said that trading during 2007 had been in line with forecasts, with revenues increasing around 9% on the year-earlier period.
Dundee-headquartered Axis said that the improvement has been largely due to increased sales contributions from the Afinion and NycoCard point-of-care systems, as well as from diagnostic products used in combination with US health care major Abbott Laboratories' AxSYM immunoassay platform. The firm added that the establishment of its Swiss division, Axis-Shield AG, and associated distribution network, would provide a further boost for revenues due to the country's healthy PoC market.
Homocysteine hurt by unlicensed products
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze